Back to top
more

ABIOMED, Inc. (ABMD)

(Delayed Data from NSDQ)

$271.75 USD

271.75
1,074,902

+6.98 (2.64%)

Updated May 3, 2019 04:00 PM ET

After-Market: $271.72 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Headquartered in Danvers, MA and founded in 1981, ABIOMED Inc. (ABMD) is engaged in developing, manufacturing and marketing of medical products, designed to assist or replace the pumping function of the failing heart. Abiomed’s main product line - Impella - comprises Impella 2.5, Impella 5.0, Impella LD, Impella CP and Impella RP.

Here's Why You Should Hold on to Insulet (PODD) Stock For Now

by Zacks Equity Research

Investors are optimistic about Insulet (PODD) on robust uptake of the Omnipod system and bullish guidance.

Here's Why You Should Retain Zimmer Biomet (ZBH) Stock For Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) given robust demand for its ROSA robotics line and continued investment in profitable business areas.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

Here's Why You Should Hold on to Haemonetics (HAE) For Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE) given the strength in its Hemostasis Management franchise and increased product uptake.

DexCom (DXCM) G6 CGM System Now Available to TRICARE Members

by Zacks Equity Research

The availability of DexCom's (DXCM) G6 CGM System to diabetic TRICARE military members is expected to enable them to make better real-time decisions about their health.

Fresenius Medical (FMS) Launches Campaign to Boost Kidney Care

by Zacks Equity Research

Fresenius Medical's (FMS) My Reason campaign will help scientists understand genetic variations in patients with chronic kidney disease in a better way.

Illumina (ILMN) Hurt by Rising Costs, Tough Competition

by Zacks Equity Research

Regulatory complications are raising the legal expenses for Illumina (ILMN), thereby building pressure on the bottom line.

NEOGEN (NEOG) Adds to Prozap Insect Control Product Line-up

by Zacks Equity Research

NEOGEN's (NEOG) latest Prozap Protectus Pour-On Insecticide- IGR product relieves cattle from infestations.

Here's Why You Should Hold on to Cardiovascular Systems (CSII)

by Zacks Equity Research

Investors are optimistic about Cardiovascular Systems' (CSII) robust international growth and upcoming launches.

IDEXX (IDXX) CAG Sales Gain Traction, FX Headwind Persists

by Zacks Equity Research

IDEXX (IDXX) has been witnessing continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.

Here's Why You Should Retain Boston Scientific (BSX) For Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific's (BSX) robust organic sales and strategic buyouts.

Here's Why You Should Retain Thermo Fisher (TMO) For Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher's (TMO) better-than-expected fourth-quarter results and impressive COVID-19 response-related revenues.

Abiomed (ABMD) Announces Successful Usage of Impella in Japan

by Zacks Equity Research

Continued adoption of Abiomed's (ABMD) Impella 5.5 with SmartAssist is likely to provide a minimally invasive surgical option for acute heart failure patients.

STERIS (STE) Up 8% Since Q3 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) robust segmental growth and noteworthy acquisitions in the healthcare and pharmaceutical spaces.

Here's Why You Should Retain Charles River (CRL) Stock For Now

by Zacks Equity Research

Investors are optimistic about Charles River's (CRL) strong segmental growth and notable partnerships.

AngioDynamics (ANGO) Q3 Earnings Top Estimates, Revenues Lag

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in its Med Tech business as well as domestic revenues in third-quarter fiscal 2022.

Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now

by Zacks Equity Research

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Here's Why You Should Retain Abiomed (ABMD) Stock For Now

by Zacks Equity Research

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Abiomed (ABMD) Beats on Q3 Earnings, Narrows FY22 Guidance

by Zacks Equity Research

Abiomed's (ABMD) strength in Impella product revenues drives its Q3 top line.

Abiomed (ABMD) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Abiomed (ABMD) delivered earnings and revenue surprises of 15.31% and 3.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Abiomed (ABMD) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q3 sales.

Analysts Estimate Abiomed (ABMD) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STERIS (STE) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

The ongoing integration of Cantel Medical business and robust demand from medical device customers are expected to have contributed to STERIS' (STE) Q3 performance.

Stryker (SYK) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) fourth-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.

Why Abiomed (ABMD) Could Beat Earnings Estimates Again

by Zacks Equity Research

Abiomed (ABMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.